Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|November 28, 2014

GE Showcases Breast Tomosynthesis Solution

GE will demonstrate at RSNA 2014 its newly FDA-approved tomosynthesis solution.

GE Healthcare will showcase at RSNA 2014 its new breast imaging 3D tomosynthesis solution, SenoClaire.

SenoClaire, which received FDA approval in August, uses a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a “step-and-shoot” method, which removes the potential from motion from the tube helping to preserve microcalcification sharpness and avoid image blur, GE said.

The SenoClaire has no increase in dose from a 2D standard mammogram to a 3D view, GE said.

[[{"type":"media","view_mode":"media_crop","fid":"29834","attributes":{"alt":"GE SenoClaire","class":"media-image media-image-right","id":"media_crop_954194364083","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"3114","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 240px; width: 300px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":"GE SenoClaire","typeof":"foaf:Image"}}]]


Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.